摘要:
The invention relates to an ultraviolet to green light region silicate phosphor capable of being excited by radiation light source and its manufacturing method, particularly to white and multicolor systems light-emitting device. The material has luminous color in the range from blue to red color system. The essential composition of the phosphor is aMO.bM′O.SiO2.cR:xEu.yLn.zLv.δLm, wherein M is an element or a combination of elements selected from the group consisting of Sr, Ca, Ba and Zn; M′ is an element or a combination of elements selected from the group consisting of Mg, Cd and Be; R is one or two of B2O3 and P2O5; Ln is an element or a combination of elements selected from the group consisting of Nd, Dy, Ho, Tm, La, Ce, Er, Pr, Bi, Sm, Sn, Y, Lu, Ga, Sb, Tb, Mn and Pb; Lv is an element or a combination of elements selected from the group consisting of Cl, F, Br, I and S; Lm is an element or a combination of elements selected from the group consisting of Li, Na and K
摘要:
The invention relates to an ultraviolet to green light region silicate phosphor capable of being excited by radiation light source and its manufacturing method, particularly to white and multicolor systems light-emitting device. The material has luminous color in the range from blue to red color system. The essential composition of the phosphor is aMO.bM′O.SiO2.cR:xEu.yLn.zLv.δLm, wherein M is an element or a combination of elements selected from the group consisting of Sr, Ca, Ba and Zn; M′ is an element or a combination of elements selected from the group consisting of Mg, Cd and Be; R is one or two of B2O3 and P2O5; Ln is an element or a combination of elements selected from the group consisting of Nd, Dy, Ho, Tm, La, Ce, Er, Pr, Bi, Sm, Sn, Y, Lu, Ga, Sb, Tb, Mn and Pb; Lv is an element or a combination of elements selected from the group consisting of Cl, F, Br, I and S; Lm is an element or a combination of elements selected from the group consisting of Li, Na and K.
摘要:
A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.
摘要:
Apparatus (systems) and methods are described for generating and displaying a virtual true 3D image viewable by a single eye of a viewer. A fixed-curve mirror is translated along an optical axis in synchrony with a temporally-modulated 2D image generator to generate a virtual image in multiple virtual image planes, enabling depth perception of the image by a single eye of the viewer.
摘要:
Techniques are disclosed for generating an ensemble model from multiple data sources. In one embodiment, the ensemble model is generated using a global validation sample, a global holdout sample and base models generated from the multiple data sources. An accuracy value may be determined for each base model, on the basis of the global validation dataset. The ensemble model may be generated from a subset of the base models, where the subset is selected on the basis of the determined accuracy values.
摘要:
Provided are techniques for analyzing fields. Statistical metrics for each field in a data set are received. A general interestingness index is generated for each field using one or more combination functions that aggregate standardized interestingness sub-indexes. One or more fields are identified as interesting for further analysis using the general interestingness index. One or more expert recommendations for field transformations are constructed for the identified one or more fields.
摘要:
The specification and drawings present a new method, apparatus and software related product (e.g., computer readable memory) for implementing a device-to-device communication of cellular, e.g., LTE, wireless devices on a shared band (e.g., ISM 2.4 GHz band), including the signaling and procedure design for contending or coordinating with the already existing radio systems (e.g., WLAN systems).
摘要:
There are disclosed a method of and system and apparatus for performing an uplink feedback, applicable to a dynamic sub-frame system, so as to avoid collision of ACK/NACK resources between a non-dynamic system and a dynamic system from occurring. The method includes: determining ACK/NACK resource for carrying ACK/NACK, corresponding to downlink data in a sub-frame n according to a set of sub-frames including a sub-frame in which the downlink data is received; and transmitting ACK/NACK information corresponding to the downlink data over the ACK/NACK resource in the sub-frame n, wherein the set of sub-frames includes a first set of sub-frames and/or a second set of sub-frames; the set of sub-frames is determined by obtained uplink/downlink sub-frame configuration information and flexible sub-frame information; the uplink/downlink sub-frame configuration information indicates the type of each sub-frame in a radio frame as an uplink sub-frame, a downlink sub-frame and a special sub-frame; and the flexible sub-frame information indicates the type of each sub-frame in a radio frame as an uplink sub-frame, a downlink sub-frame, a special sub-frame and a flexible sub-frame, wherein the flexible sub-frame can be used for transmission of uplink or downlink data.
摘要:
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要:
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.